Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden

Fig. 4

On ROC curve analyses in HER2BC and HRBC patients. ROC analysis showed that, for HER2BC patients, the results for the RCB-TILs (AUC: 0.687) were better than those for the TILs (AUC: 0.681) and the RCB (AUC: 0.539) (a–d). ROC analysis for HRBC patients also found similar results (AUC: TILs = 0.501, RCB = 0.622, RCB-TILs = 0.650) (e-h)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us